PFE Pfizer Inc.

42.16
-0.11  -0%
Previous Close 42.27
Open 41.99
Price To Book 3.42
Market Cap 243704808208
Shares 5,780,474,578
Volume 23,178,800
Short Ratio 1.72
Av. Daily Volume 25,890,170

SEC filingsSee all SEC filings

  1. 8-K - Current report 181248193
  2. 8-K - Current report 181242295
  3. 8-K - Current report 181222164
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 initiation announced December 13, 2017.
PF-04965842
Moderate-to-severe atopic dermatitis (AD)
Approval announced December 13, 2017.
IXIFI
Remicade (infliximab) biosimilar
Phase 3 data released November 28, 2017 - primary endpoint not met.
Avelumab
Gastric cancer
Approval announced October 12, 2017.
LYRICA (pregabalin)
Postherpetic neuralgia (PHN)
Advisory Committee Meeting held November 7, 2017. No votes cast.
Staphylococcus aureus vaccine
Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Phase 3 data presented at ESMO - risk ratio of 0.940.
PF-05280014
Herceptin biosimilar
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
FDA approval announced November 2, 2018.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 3 trial initiated March 2017. Data due 2020.
PF-06425090
C. difficile Infection
Phase 3 trial met primary endpoint - December 20, 2018.
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 ongoing. Primary completion date estimated mid-2020.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
FDA approval announced July 13, 2018.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
Approval announced May 30, 2018.
Xeljanz
Ulcerative colitis
Approval announced December 14, 2017.
Xeljanz
Psoriatic arthritis
FDA Approval announced October 16, 2018.
Talazoparib
BRCA-mutated breast cancer
Approval announced 16 November, 2017.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Approval announced December 19, 2017.
BOSULIF (BOSUTINIB)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
Phase 3 data due 1H 2019.
Tanezumab
Chronic low back pain
Phase 3 data released July 18, 2018 - co-primary endpoints met.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 data due 2Q 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Approved Sept 10 2014
XTANDI
Cancer - mCRPC who have not received chemotherapy
PDUFA date November 2019. Exact date not provided. Estimate November 14, 2019.
Tafamidis (tafamidis free acid form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA Approval announced September 27, 2018.
Dacomitinib
Non-small cell lung cancer (NSCLC)
BsUFA date 3Q 2019.
PF-05280586 (Biosimilar to Rituxan/ MabThera)
CD20-positive, low tumor burden, follicular lymphoma
Phase 3 trial discontinued due to futility.
INLYTA (axitinib)
Recurrent renal cell carcinoma (RCC)
Phase 1b initiation announced April 12, 2018. Early data due 1H 2019.
PF-06939926
Duchenne muscular dystrophy (DMD)
Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously).
IBRANCE - PALOMA-3
Breast cancer
Phase 3 presentation at ASCO June 2018.
IBRANCE (palbociclib)
Head and neck squamous cell carcinoma
FDA approval announced November 21, 2018.
Glasdegib
Acute myeloid leukemia (AML)
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 2 development terminated due to lack of efficacy.
Domagrozumab
Duchenne muscular dystrophy (DMD)
Phase 3 interim analysis September 11, 2018 showed improvement in PFS.
BAVENCIO (avelumab) and INLYTA (axitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoints of PFS and OS.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
BsUFA date 2Q 2019.
PF-06439535
Biosimilar bevacizumab
BsUFA date 1Q 2019.
PF-05280014
Herceptin biosimilar
Phase 3 data released July 18, 2018 - co-primary endpoints met. 24-week data due 1H 2019.
Tanezumab
Osteoarthritis
Phase 3 trial to be terminated due to lack of efficacy.
Avelumab - JAVELIN Ovarian 100
Ovarian cancer
Phase 2b/3 initiation announced January 3, 2018.
PF-06651600
Alopecia areata
PDUFA date under priority review July 2019. Exact date not provided. Estimate July 14, 2019.
Tafamidis (tafamidis meglumine form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)

SEC Filings

  1. 8-K - Current report 181248193
  2. 8-K - Current report 181242295
  3. 8-K - Current report 181222164
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170256
  6. 8-K - Current report 181145595
  7. SC 13D - General statement of acquisition of beneficial ownership
  8. 8-K - Current report 181098180
  9. 8-K - Current report 181060774
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181058148